Cargando…
S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE
Autores principales: | Hernández-Sánchez, A., Villaverde-Ramiro, Á., Martínez Elicegui, J., González, T., Benner, A., Sträng, E., Castellani, G., Heckman, C. A., Versluis, J., Abáigar, M., Sobas, M., Azibeiro, R., Tur, L., Valk, P. J., Metzeler, K. H., Ayala, R., Dall’Olio, D., Tettero, J., Martínez-López, J., Dombret, H., Pratcorona, M., Damm, F., Mills, K. I., Mayer, J., Thiede, C., Voso, M. T., Sanz, G. F., Calado, F., Döhner, K., Gaidzik, V. I., Heuser, M., Haferlach, T., Turki, A. T., Reinhardt, D., Villoria Medina, R., van Speybroeck, M., Schulze-Rath, R., Barbus, M., Butler, J. E., Hernández Rivas, J. M., Huntly, B. J., Ossenkoppele, G. J., Döhner, H., Bullinger, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9642067/ http://dx.doi.org/10.1097/01.HS9.0000843412.59637.1b |
Ejemplares similares
-
Randomized phase-III study of low-dose cytarabine and etoposide + /− all-trans retinoic acid in older unfit patients with NPM1-mutated acute myeloid leukemia
por: Schlenk, R. F., et al.
Publicado: (2023) -
Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine
por: Schlenk, R. F., et al.
Publicado: (2019) -
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
por: Cocciardi, Sibylle, et al.
Publicado: (2019) -
Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia
por: Schlenk, R F, et al.
Publicado: (2017) -
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
por: Nagel, Gabriele, et al.
Publicado: (2017)